Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Deutsche Bank AG (USA) (DB): Insiders Aren’t Crazy About It But Hedge Funds Love It

Page 1 of 2

What’s a smart Deutsche Bank AG (USA) (NYSE:DB) investor to do?

In the financial world, there are tons of methods investors can use to monitor the equity markets. A couple of the best are hedge fund and insider trading interest. At Insider Monkey, our studies have shown that, historically, those who follow the top picks of the best money managers can outclass the broader indices by a healthy amount (see just how much).

Equally as key, bullish insider trading activity is another way to look at the marketplace. As the old adage goes: there are a variety of incentives for an executive to sell shares of his or her company, but only one, very simple reason why they would buy. Various empirical studies have demonstrated the impressive potential of this method if piggybackers understand where to look (learn more here).

Thus, it’s important to study the latest info surrounding Deutsche Bank AG (USA) (NYSE:DB).

Hedge fund activity in Deutsche Bank AG (USA) (NYSE:DB)

At Q2’s end, a total of 13 of the hedge funds we track held long positions in this stock, a change of 18% from the previous quarter. With hedge funds’ positions undergoing their usual ebb and flow, there exists an “upper tier” of noteworthy hedge fund managers who were upping their holdings substantially.

Deutsche Bank AG (USA) (NYSE:DB)According to our 13F database, Crispin Odey’s Odey Asset Management Group had the most valuable position in Deutsche Bank AG (USA) (NYSE:DB), worth close to $13.6 million, comprising 0.5% of its total 13F portfolio. Sitting at the No. 2 spot is Matthew Hulsizer of PEAK6 Capital Management, with a $10.7 million call position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Other hedge funds that hold long positions include Jim Simons’s Renaissance Technologies, Matthew Knauer and Mina Faltas’s Nokota Management and Steven Cohen’s SAC Capital Advisors.

With a general bullishness amongst the titans, certain bigger names have jumped into Deutsche Bank AG (USA) (NYSE:DB) headfirst. Odey Asset Management Group, managed by Crispin Odey, assembled the most outsized position in Deutsche Bank AG (USA) (NYSE:DB). Odey Asset Management Group had 13.6 million invested in the company at the end of the quarter. Matthew Hulsizer’s PEAK6 Capital Management also made a $10.7 million investment in the stock during the quarter. The other funds with brand new DB positions are Jim Simons’s Renaissance Technologies, Matthew Knauer and Mina Faltas’s Nokota Management, and Steven Cohen’s SAC Capital Advisors.

How are insiders trading Deutsche Bank AG (USA) (NYSE:DB)?

Insider buying is best served when the company in question has seen transactions within the past six months. Over the last 180-day time period, Deutsche Bank AG (USA) (NYSE:DB) has seen zero unique insiders buying, and zero insider sales (see the details of insider trades here).

We’ll also review the relationship between both of these indicators in other stocks similar to Deutsche Bank AG (USA) (NYSE:DB). These stocks are Banco Bradesco SA (ADR) (NYSE:BBD), Sumitomo Mitsui Financial Grp, Inc. (ADR) (NYSE:SMFG), ICICI Bank Limited (ADR) (NYSE:IBN), Mizuho Financial Group Inc. (ADR) (NYSE:MFG), and Banco Bilbao Vizcaya Argentaria SA (ADR) (NYSE:BBVA). This group of stocks are in the foreign regional banks industry and their market caps are similar to DB’s market cap.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!